RenovoRx Q3 revenue rises to $1.07 million; net loss widens and 2026 guidance is held
RenovoRx reported third-quarter 2026 revenue of $1.07 million, up from $266,000 a year earlier, and kept its full-year 2026 revenue guidance of $3.75 million to $4.25 million. The net loss widened to $3.6 million, or $0.08 per share, from $2.9 million, as selling, general and administrative expenses rose to $2.9 million from $1.7 million, so shareholders see faster sales growth alongside higher losses.
Key points
- Q3 2026 revenue was $1.07 million versus $266,000 in Q3 2025; gross margin was about 82%.
- Net loss was $3.6 million ($0.08 per share) versus $2.9 million ($0.08 per share) a year earlier.
- Selling, general and administrative expenses were $2.9 million versus $1.7 million, which the company attributed to building commercial infrastructure.
- Cash and cash equivalents were $10.4 million at September 30, 2026; the company says cash is sufficient into the second half of 2027.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.